Riskpilot← Back to searchSign inGet full accessSentry BioPharma Services ApS
APSActiveCVR 41330619Nybrogade 12Warehousing and storage · NACE 5210Est. 20201 employees
Revenue 2024
—
EBITDA margin
—
+37% vs 2023
Equity ratio
-238.6%
Financial strength
Net profit 2024
DKK -3,3M
+9% vs 2023
| Revenue | — | — |
| EBITDA | DKK -2,4M | +37% |
| Net profit | DKK -3,3M | +9% |
| Total assets | DKK 4,6M | +30% |
| Equity | DKK -11,1M | -42% |
| Employees | 1 | — |
Legal name
Sentry BioPharma Services ApS
CVR number
41330619
Legal form
Anpartsselskab
NACE code
5210 · Warehousing and storage
Founded
27. april 2020
Share capital
DKK 40.000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør
Company purpose
Selskabets formål er at levere køleopbevaringsydelser til farmaceutiske materialer og dertil forbunden virksomhed.
Address
Nybrogade 12
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Staff expenses | -0 | -0 | -0 | -422 | -486 |
| EBITDA | -382 | -776 | -2.187 | -3.797 | -2.406 |
| Depreciation & amort. | -0 | -0 | -819 | -0 | -0 |
| EBIT | -382 | -776 | -3.006 | -3.797 | -2.406 |
| Net financials | 19 | -280 | 184 | -254 | -1.538 |
| Profit before tax | -362 | -1.056 | -2.821 | -3.615 | -3.276 |
| Tax | -0 | -0 | -0 | -0 | -0 |
| Net profit | -362 | -1.056 | -2.821 | -3.615 | -3.276 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2.723 | 3.079 | 2.695 | 3.574 | 4.647 |
| Equity | -322 | -1.378 | -4.199 | -7.814 | -11.090 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 3.045 | 4.457 | 6.894 | 11.388 | 15.737 |
| Total debt | 3.045 | 4.457 | 6.894 | 11.388 | 15.737 |
EBITDA margin
-240576300.0%
This company
15.8%
Market median
-1522634910% vs market
20202024
Equity ratio
-238.6%
This company
38.2%
Market median
-725% vs market
20202024
Return on equity
-327551800.0%
This company
18.4%
Market median
-1780172926% vs market
20202024
Net profit margin
-327551800.0%
This company
8.1%
Market median
-4043849483% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
1.42×
This company
0.62×
Market median
-129% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-04-27 – 2020-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
OM Management | Management | 2022 | — | — |
TJ Management | Management | 2020 | — | — |
WM Management | Management | 2023 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2020 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Sentry BioPharma Services ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ole Meier Sørensen | Management | 0 companies |
| Timothy Jon Mitchell | Management | 0 companies |
| William Maxwell Tuttle | Management | 0 companies |